Abraxis Bioscience, Inc. (NASDAQ: ABBI) is a strategically integrated pharmaceutical company that manufactures, markets and develops injectable products, with a focus on oncology and anti-infectives. Acquired by Celgene.
Achillion Pharmaceuticals (NASDAQ: ACHN) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates. Acura’s lead product, Oxecta, has been approved by the FDA and is partnered with Pfizer.
AMAG Pharmaceuticals (NASDAQ: AMAG) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
APT Pharmaceuticals is a clinical-stage company developing products to treat respiratory diseases.
Aspreva Pharmaceuticals (NASDAQ: ASPV) is a pharmaceutical company which identifies, develops and commercializes new applications for existing medicines. Acquired by Galenica.
Avanir Pharmaceuticals (NASDAQ: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. The company's lead product, Nuedexta, has been approved by the FDA for the treatment of pseudobulbar affect.
Biodel, Inc. is a biopharmaceutical drug delivery company with novel products in development for the treatment of diabetes.
BioForm Medical, Inc. is developing and commercializing Radiesse and Coaptite, proprietary gels containing calcium hydroxylapatite, for cosmetic applications, stress urinary incontinence (SUI), vocal cord insufficiency and paralysis (VFI), and other disorders. Acquired by Merz.
Chelsea Therapeutics (NASDAQ: CHTP) acquires, develops and commercializes innovative products for the treatment of important unmet medical needs such as rheumatoid arthritis, psoriasis, and other inflammatory conditions.
CoTherix (NASDAQ: CTRX) is marketing Ventavis® (iloprost aerosol) for the treatment of primary pulmonary hypertension, an orphan indication, for the U.S. market. Acquired by Actelion.
Dynavax Technologies (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.
Hamilton Pharmaceuticals, Inc. (HPI) is developing novel treatments for central nervous system disease. Acquired by Neuren.
InterMune (NASDAQ: ITMN) is a biopharmaceutical company focused on the applied research, development and marketing of life-saving therapies for pulmonary diseases.
NeoMend, Inc. is a medical device company commercializing ProGel Pleural Air Leak Sealant for lung air leaks. The company has a proprietary platform technology which seals and facilitates healing of soft tissue wounds caused by trauma or surgical procedures. Acquired by Bard.
NextWave Pharmaceuticals is focused on developing innovative products for the pediatric pharmaceutical market. The company is developing and commercializing products that address many of the compliance, convenience, dosing and safety issues children and their parents face today. Acquired by Pfizer.
Prestwick Pharmaceuticals is a specialty pharmaceutical company engaged in the development and marketing of drugs for diseases of the CNS. Acquired by Biovail.
Transcept Pharmaceuticals is developing products that utilize the company's proprietary drug delivery system. The company’s lead product, Intermezzo, has been approved by the FDA and is partnered with Purdue Pharma.
Tranzyme Pharma (NASDAQ:TZYM) is developing novel GI therapeutics.
Vicept Therapeutics is developing novel products for the treatment of rosacea and other dermatological conditions. Acquired by Allergan.
YM BioSciences (NYSE: YMI) is a pharmaceutical company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. Acquired by Gilead Sciences.